Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: Prospective randomized trial

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 12, 2009, Pages 4938-4945

  Banaszewska, Beata ^a   Pawelczyk, Leszek ^a   Spaczynski, Robert Z ^a   Duleba, Antoni J ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FOLLITROPIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; METFORMAX; METFORMIN; PRASTERONE SULFATE; SIMVACHOL; SIMVASTATIN; TESTOSTERONE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; UNIVERSITY HOSPITAL;

EID: 73249141771     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1674     Document Type: Article

References (47)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO 2004 The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745-2749
2. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI 1999 A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84:4006-4011
3. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF 2000 A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85:2434-2438
4. Dahlgren E, Janson PO, Johansson S, Lapidus L, Odén A 1992 Polycystic ovary syndrome and risk for myocardial infarction. Acta Obstet Gynecol Scand 71:599-604
5. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS 2006 Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 91:1357-1363
6. Dunaif A, Segal KR, Futterweit W, Dobrjansky A 1989 Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165-1174
7. Wild RA, Applebaum-Bowden D, Demers LM, Bartholomew M, Landis JR, Hazzard WR, Santen RJ 1990 Lipoprotein lipids in women with androgen excess: independent associations with increased insulin and androgens. Clin Chem 36:283-289
8. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N 2001 Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86:2453-2455
9. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L 1995 Coronary heart disease risk factors inwomenwith polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 15:821-826
10. Azziz R, Marin C, Hoq L, Badamgarav E, Song P 2005 Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 90:4650-4658
11. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M 2000 Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85:139-146
12. Banaszewska B, Duleba AJ, Spaczynski RZ, Pawelczyk L 2006 Lipids in polycystic ovary syndrome: role of hyperinsulinemia and effects of metformin. Am J Obstet Gynecol 194:1266-1272
13. Lord J, Thomas R, Fox B, Acharya U, Wilkin T 2006 The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome - a randomised, doubleblind, placebo-controlled trial. BJOG 113:817-824
14. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, Piperi C, Papamichael C, Aessopos A, Lekakis J, Mavrikakis M 2005 Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol 152:749-756
15. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK 1998 Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 69:691-696
16. Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Martínez-Bermejo E, Lasunción MA, Escobar-Morreale HF 2007 Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 92:2453-2461
17. Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L 2006 Simvastatin improves biochemical parameters inwomenwith polycystic ovary syndrome: results of a prospective, randomized trial. Fertil Steril 85:996-1001
18. Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ 2007 Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab 92:456-461
19. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL 2009 The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab 94:103-108
20. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF 2006 Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91:4237-4245
21. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF, Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen E, Society P 2009 The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91:456-488
22. Balen AH, Laven JS, Tan SL, Dewailly D 2003 Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 9:505-514
23. Ferriman D, Gallway JD 1961 Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440-1447
24. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L 2000 Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 73:1149-1154
25. Vermeulen A, Verdonck L, Kaufman JM 1999 A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666-3672
26. Matsuda M, DeFronzo RA 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470
27. Goldstein JL, Brown MS 1990 Regulation of the mevalonate pathway. Nature 343:425-430
28. Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K, Tonn JC 2000 Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res 20:2761-2771
29. Wassmann S, Laufs U, Bäumer AT, Müller K, Konkol C, Sauer H, Böhm M, Nickenig G 2001 Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 59:646-654
30. Engelhardt H, Gore-Langton RE, Armstrong DT 1989 Mevinolin (lovastatin) inhibits androstenedione production by porcine ovarian theca cells at the level of the 17 α-hydroxylase:C-17,20-lyase complex. Endocrinology 124:2297-2304
31. Izquierdo D, Foyouzi N, Kwintkiewicz J, Duleba AJ 2004 Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil Steril 82(Suppl 3):1193-1197
32. Hughesdon PE 1982 Morphology and morphogenesis of the Stein-Leventhal ovary and of so called "hyperthecosis." Obstet Gynecol Surv 37:59-77
33. Gilling-Smith C, Story H, Rogers V, Franks S 1997 Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 47:93-99
34. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB 1985 Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 61:946-951
35. Holte J, Bergh T, Berne C, Lithell H 1994 Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (Oxf) 41:463-471
36. Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson Jr SK 1996 Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol 174:1224-1229; discussion 1229-1232
37. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, Katsilambros N, Kreatsas G, Panidis D 2006 Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 21:1426-1431
38. Nielsen S, Schmitz O, Møller N, Pørksen N, Klausen IC, Alberti KG, Mogensen CE 1993 Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 36:1079-1086
39. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Park JB, Shin EK 2009 Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 204:483-490
40. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS 2000 Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod 15:1266-1274
41. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS 2008 The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 93:4299-4306
42. Orio Jr F, Palomba S, Cascella T, De Simone B, Manguso F, Savastano S, Russo T, Tolino A, Zullo F, Lombardi G, Azziz R, Colao A 2005 Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab 90:6072-6076
43. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH 2006 Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 21:80-89
44. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE 2001 Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174
45. Fisslthaler B, Fleming I, Keserü B, Walsh K, Busse R 2007 Fluid shear stress and NO decrease the activity of the hydroxy-methylglutaryl coenzyme A reductase in endothelial cells via the AMP-activated protein kinase and FoxO1. Circ Res 100:e12-e21
46. Barber TM, Wass JA, McCarthy MI, Franks S 2007 Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 66:513-517
47. Edison RJ, Muenke M 2004 Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A 131: 287-298